Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.46 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056146 | 0.99 | NPC1 (0.47) | MEN1KMT2ANPC1DRD2HTR1A | |
| SCHEMBL2457566 | 0.99 | NPC1 (0.47) | MEN1KMT2ANPC1DRD2HTR1A | |
| SCHEMBL17928899 | 0.84 | KMT2A (0.45) | MEN1KMT2ANPC1DRD2HTR1A | |
| SCHEMBL251855 | 0.80 | CXCR2 (0.55) | MEN1KMT2ADRD2CXCR2DRD3 | |
| SCHEMBL252140 | 0.80 | CXCR2 (0.55) | MEN1KMT2ADRD2CXCR2DRD3 | |
| Hydrochloric Acid SCHEMBL5569882 | 0.79 | CXCR2 (0.54) | MEN1KMT2ADRD2CXCR2DRD3 | |
| Hydrochloric Acid SCHEMBL251520 | 0.79 | CXCR2 (0.54) | MEN1KMT2ADRD2CXCR2DRD3 | |
| SCHEMBL252131 | 0.78 | CXCR2 (0.56) | MEN1KMT2ADRD2CXCR2DRD1 | |
| SCHEMBL2556708 | 0.78 | CXCR2 (0.56) | MEN1KMT2ADRD2CXCR2DRD1 | |
| Hydrochloric Acid SCHEMBL253136 | 0.78 | CXCR2 (0.55) | MEN1KMT2ADRD2CXCR2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646203-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2025-11-12 | — | — | EP | claimed |
| US-20250170316-A1 | PERITONEAL DIALYSIS FLUID COMPOSITION COMPRISING A COMPLEMENT INHIBITOR | Invizius Limited (GB) | 2025-05-29 | — | — | US | claimed |
| EP-4486369-A1 | PERITONEAL DIALYSIS FLUID COMPOSITION COMPRISING A COMPLEMENT INHIBITOR | Invizius Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| CN-118742318-A | Peritoneal dialysis fluid composition comprising complement inhibitor | 因维齐乌斯有限公司 | 2024-10-01 | — | — | CN | claimed |
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| WO-2023161662-A1 | PERITONEAL DIALYSIS FLUID COMPOSITION COMPRISING A COMPLEMENT INHIBITOR | Invizius Limited (GB) | 2023-08-31 | — | — | WO | claimed |
| WO-2022025168-A1 | CONTROL OF ACTIVATION OF MAST CELLS AND BASOPHILS VIA COAGULATION/FIBRINOLYSIS SYSTEM AND COMPLEMENT, AND PHARMACEUTICAL USE THEREOF | 国立大学法人広島大学 | 2022-02-03 | — | — | WO | claimed |
| EP-1951663-B1 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-20 | — | — | EP | claimed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | claimed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | claimed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3723744-B1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE FARM SPA (IT) | 2026-03-18 | — | — | EP | disclosed |
| EP-4706762-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici SpA (IT) | 2026-03-11 | — | — | EP | disclosed |
| EP-4308114-B1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE FARM SPA (IT) | 2026-02-11 | — | — | EP | disclosed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR1, CCR8 | MEN1 4749/4885KMT2A 4790/4885NPC1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.